aminolevulinic acid has been researched along with Local Neoplasm Recurrence in 203 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECT There is evidence that 5-aminolevulinic acid (ALA) facilitates greater extent of resection and improves 6-month progression-free survival in patients with high-grade gliomas." | 9.22 | A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. ( Berger, MS; Chang, S; Hervey-Jumper, SL; Lau, D; McDermott, MW; Molinaro, AM; Phillips, JJ, 2016) |
| "Several studies have shown that 5-aminolevulinic acid (5-ALA)-induced fluorescence cystoscopy improves the detection of superficial bladder cancer." | 9.12 | Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. ( Burger, M; Denzinger, S; Filbeck, T; Knuechel, R; Roessler, W; Walter, B; Wieland, WF, 2007) |
| " Search terms include "glioma" and "aminolevulinic acid"." | 9.05 | 5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review. ( Broekx, S; De Vleeschouwer, S; Weyns, F, 2020) |
| "Fluorescence guided surgery (FGS) with five-aminolevulinic acid (5-ALA) is expected to revolutionize neurosurgical care of patients with high-grade gliomas (HGG)." | 9.01 | 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas. ( Berger, MS; Chohan, MO, 2019) |
| "5-Aminolevulinic acid (5-ALA) has been approved as an intraoperative adjunct in glioma surgery in Europe, but not North America." | 8.93 | The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. ( Bernstein, M; Hachem, LD; Klironomos, G; Mansouri, A; Mansouri, S; Vogelbaum, MA; Zadeh, G, 2016) |
| "We conducted a meta-analysis assessing the effect of photodynamic diagnosis (PDD) -guided transurethral resection of the bladder tumor (TURB) on the recurrence-free survival in patients with non-muscle invasive bladder cancer within prospective randomised trials that used 5-aminolevulinic acid as a photosensitizer." | 8.93 | [A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect ( Evmenenko, AA; Rolevich, AI, 2016) |
| " This study investigated the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in destructing glioma stem cells (GSCs), including the mesenchymal subtype (MES-GSCs) demonstrated to have the lowest radio- and chemosensitivity." | 8.31 | Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells. ( Fujishiro, T; Fukunaga, K; Furuse, M; Hiramatsu, R; Hosomi, R; Ikeda, N; Kajimoto, Y; Kawabata, S; Kuroiwa, T; Nakano, I; Nonoguchi, N; Omura, N; Park, Y; Wanibuchi, M; Yagi, R, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence)." | 8.31 | Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. ( Hirata, H; Hiroyoshi, T; Isoyama, N; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nakamura, K; Oka, S; Shiraishi, K, 2023) |
| "Photodynamic diagnosis (PDD) with administration of oral aminolevulinic acid (ALA) prior to transurethral resection of bladder tumor (TURBT) can now be used for non-muscle invasive bladder cancer (NMIBC) in clinical settings in Japan." | 8.12 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The aim of this study is to compare the use of 5-aminolevulinic acid (5-ALA) and sodium fluorescein (SF) in IV ventricular ependymoma (IVEP) surgical resection." | 8.12 | 5-aminolevulinic acid and sodium fluorescein in IV ventricle ependymoma surgery: preliminary experience comparing the two techniques. ( Becattini, E; Boschi, A; Buccoliero, A; Della Puppa, A; Lastrucci, G; Pisano, A, 2022) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 8.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "To explore the therapeutic effect of topical 5-Aminolevulinic Acid photodynamic therapy (ALA-PDT) on laryngeal papillomatosis (LP) treatment." | 7.91 | Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment. ( Cai, Q; Chen, R; Han, P; Huang, X; Liang, F; Lin, P; Luo, M, 2019) |
| "We determined whether photodynamic therapy after the oral administration of 5-aminolevulinic acid in patients with superficial bladder cancer that cannot be controlled by transurethral resection and intravesical bacillus Calmette-Guerin (BCG) immunotherapy would preserve the bladder, while stopping tumor progression." | 7.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "These initial clinical results suggest that photodynamic therapy with orally administered 5-aminolevulinic acid is effective as an organ preserving procedure for treating superficial bladder cancer even in patients with bacillus Calmette-Guerin refractory carcinoma." | 7.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "5-Aminolevulinic acid induced fluorescence endoscopy has outstanding sensitivity for detecting early stage bladder cancer." | 7.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "In 25 cases (53 biopsies) of a history of or suspicion for bladder cancer 5-aminolevulinic acid induced fluorescence endoscopy and fluorescence image quantification were performed." | 7.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "To report clinical experience with intravesical instillations of 5-aminolevulinic acid (ALA) for the photodynamic therapy of superficial bladder cancer and to assess any side-effects of the treatment." | 7.69 | Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Lumper, W; Waidelich, R, 1996) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 6.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "5-Aminolevulinic acid (5-ALA) has been approved as an intraoperative adjunct in glioma surgery in Europe, but not North America." | 6.53 | The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. ( Bernstein, M; Hachem, LD; Klironomos, G; Mansouri, A; Mansouri, S; Vogelbaum, MA; Zadeh, G, 2016) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | 5.91 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "This study compared tumor recurrence among NMIBC patients who underwent TURBT under either white light cystoscopy (WL) or PDD." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence in NMIBC patients (cumulative number of recurrences/cumulative number of follow-up days, number of recurrences/10,000 days), including progression to muscle-invasive bladder cancer (MIBC), was 12." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence was lower and the time to recurrence was longer in the PDD-TURBT group than in the WL-TURBT group." | 5.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 5.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Cervical high-grade squamous intraepithelial lesions (HSIL), as pre-cancerous lesions, have a 5% chance of progressing to invasive cancer." | 5.72 | The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions. ( Cao, L; Qin, L; Shen, Y; Su, Y; Tang, Y; Wang, B; Wang, L; Zhang, L; Zhang, M; Zhang, T; Zhang, Y; Zhou, Y, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 5.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Anal canal condylomata acuminata is a disease caused by the human papilloma virus." | 5.56 | Advanced application of holmium: YAG laser combined ALA-PDT for the treatment of refractory condylomata acuminata in anal canal. ( Liao, C; Sun, X; Wang, X; Zhang, G; Zhang, H; Zhang, L, 2020) |
| "A total of six cases of ulcerative squamous cell carcinoma were included in our study." | 5.56 | Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for the treatment of ulcerative squamous cell carcinoma. ( Dong, L; Li, X; Lu, Y; Shen, X; Wang, Y; Zhang, J; Zhang, W, 2020) |
| "The detection rate of HPV infections was 76." | 5.51 | Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment. ( Cai, Q; Chen, R; Han, P; Huang, X; Liang, F; Lin, P; Luo, M, 2019) |
| "To assess the efficacy of two treatment options for non-muscle-invasive bladder cancer (NMIBC): (1) transurethral resection (TUR) guided by fluorescence cystoscopy (FC) with the use of 5-aminolevulinic acid (5-ALA) and (2) single early instillation of doxorubicin in a single-center open-label prospective randomized study with a 2 × 2 factorial design." | 5.24 | Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. ( Krasny, SA; Minich, AA; Mokhort, AA; Polyakov, SL; Rolevich, AI; Sukonko, OG; Vasilevich, VY; Zhegalik, AG, 2017) |
| "OBJECT There is evidence that 5-aminolevulinic acid (ALA) facilitates greater extent of resection and improves 6-month progression-free survival in patients with high-grade gliomas." | 5.22 | A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. ( Berger, MS; Chang, S; Hervey-Jumper, SL; Lau, D; McDermott, MW; Molinaro, AM; Phillips, JJ, 2016) |
| "The benefits of fluorescent light (FL) cystoscopy with 5-aminolevulinic acid (5-ALA) or hexaminolevulinate (HAL) in non-muscle-invasive bladder cancer (NMIBC) have been mentioned in many trials." | 5.12 | Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. ( Liu, B; Ma, X; Shen, H; Sun, J, 2021) |
| "Several studies have shown that 5-aminolevulinic acid (5-ALA)-induced fluorescence cystoscopy improves the detection of superficial bladder cancer." | 5.12 | Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. ( Burger, M; Denzinger, S; Filbeck, T; Knuechel, R; Roessler, W; Walter, B; Wieland, WF, 2007) |
| "To report a phase-1 study of patients with recurrent superficial bladder cancer treated with photodynamic therapy (PDT) using sequential mitomycin C and 5-aminolaevulinic acid (ALA)." | 5.11 | A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. ( Allman, R; Datta, SN; French, AJ; Mason, MD; Matthews, PN; Skyrme, RJ, 2005) |
| "Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established." | 5.09 | Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. ( MacKie, RM; McColl, JH; Moore, JV; Morton, CA; Whitehurst, C, 2001) |
| "One of the most valuable innovations in high-grade glioma surgery is 5-aminolevulinic acid (5-ALA)." | 5.05 | 5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review. ( Altieri, R; Barresi, V; Della Pepa, GM; Ius, T; La Rocca, G; Marchese, E; Menna, G; Olivi, A; Sabatino, G, 2020) |
| " Search terms include "glioma" and "aminolevulinic acid"." | 5.05 | 5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review. ( Broekx, S; De Vleeschouwer, S; Weyns, F, 2020) |
| "Fluorescence guided surgery (FGS) with five-aminolevulinic acid (5-ALA) is expected to revolutionize neurosurgical care of patients with high-grade gliomas (HGG)." | 5.01 | 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas. ( Berger, MS; Chohan, MO, 2019) |
| "5-Aminolevulinic acid (5-ALA) has been approved as an intraoperative adjunct in glioma surgery in Europe, but not North America." | 4.93 | The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. ( Bernstein, M; Hachem, LD; Klironomos, G; Mansouri, A; Mansouri, S; Vogelbaum, MA; Zadeh, G, 2016) |
| "We conducted a meta-analysis assessing the effect of photodynamic diagnosis (PDD) -guided transurethral resection of the bladder tumor (TURB) on the recurrence-free survival in patients with non-muscle invasive bladder cancer within prospective randomised trials that used 5-aminolevulinic acid as a photosensitizer." | 4.93 | [A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect ( Evmenenko, AA; Rolevich, AI, 2016) |
| "The clinical benefit of photodynamic diagnosis (PDD) with 5-aminolevulinic acid or hexaminolevulinate in addition to white-light cystoscopy (WLC) in bladder cancer has been discussed controversially." | 4.86 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| " This study investigated the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in destructing glioma stem cells (GSCs), including the mesenchymal subtype (MES-GSCs) demonstrated to have the lowest radio- and chemosensitivity." | 4.31 | Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells. ( Fujishiro, T; Fukunaga, K; Furuse, M; Hiramatsu, R; Hosomi, R; Ikeda, N; Kajimoto, Y; Kawabata, S; Kuroiwa, T; Nakano, I; Nonoguchi, N; Omura, N; Park, Y; Wanibuchi, M; Yagi, R, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence)." | 4.31 | Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. ( Hirata, H; Hiroyoshi, T; Isoyama, N; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nakamura, K; Oka, S; Shiraishi, K, 2023) |
| "Photodynamic diagnosis (PDD) with administration of oral aminolevulinic acid (ALA) prior to transurethral resection of bladder tumor (TURBT) can now be used for non-muscle invasive bladder cancer (NMIBC) in clinical settings in Japan." | 4.12 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The aim of this study is to compare the use of 5-aminolevulinic acid (5-ALA) and sodium fluorescein (SF) in IV ventricular ependymoma (IVEP) surgical resection." | 4.12 | 5-aminolevulinic acid and sodium fluorescein in IV ventricle ependymoma surgery: preliminary experience comparing the two techniques. ( Becattini, E; Boschi, A; Buccoliero, A; Della Puppa, A; Lastrucci, G; Pisano, A, 2022) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 4.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "5-aminolevulinic acid photodynamic therapy (ALA-PDT) is not only the first-line treatment for actinic keratosis (AK), but also demonstrated to improve photoaging during AK field treatment." | 4.02 | Long-term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: A retrospective study. ( Liu, X; Shi, L; Wang, B; Wang, P; Wang, X; Zhang, G; Zhang, L; Zhao, Z; Zhou, Z, 2021) |
| "Photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) is expected to be useful in preventing oversight of non-muscle-invasive bladder cancer (NMIBC) and in reducing the intravesical recurrence rate after transurethral resection of bladder tumor (TURBT)." | 4.02 | [Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)]. ( Inoue, T; Kanda, H; Kato, M; Masui, S; Nishikawa, K; Sasaki, T; Sugimura, Y; Sugino, Y; Yoshio, Y, 2021) |
| "5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) is a reliable treatment for actinic keratosis (AK), though the concentration of 20 % is applied in most ALA-PDT for the treatment of AK, it was found that 10 % ALA could achieve similar outcome during clinical practice." | 3.96 | Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. ( Cao, Z; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, L; Zho, Z; Zhu, L, 2020) |
| "To explore the therapeutic effect of topical 5-Aminolevulinic Acid photodynamic therapy (ALA-PDT) on laryngeal papillomatosis (LP) treatment." | 3.91 | Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment. ( Cai, Q; Chen, R; Han, P; Huang, X; Liang, F; Lin, P; Luo, M, 2019) |
| "Fluorescence-guided resection with 5-aminolevulinic acid (5-ALA), which has shown promising results in the resection of malignant gliomas, has been used for meningioma resection in an attempt to more clearly delineate the tumor margin." | 3.77 | Confocal microscopy for the histological fluorescence pattern of a recurrent atypical meningioma: case report. ( Harris, BT; Paulsen, KD; Roberts, DW; Valdes, PA; Whitson, WJ, 2011) |
| "We determined whether photodynamic therapy after the oral administration of 5-aminolevulinic acid in patients with superficial bladder cancer that cannot be controlled by transurethral resection and intravesical bacillus Calmette-Guerin (BCG) immunotherapy would preserve the bladder, while stopping tumor progression." | 3.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "These initial clinical results suggest that photodynamic therapy with orally administered 5-aminolevulinic acid is effective as an organ preserving procedure for treating superficial bladder cancer even in patients with bacillus Calmette-Guerin refractory carcinoma." | 3.71 | Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Stepp, H; Waidelich, R; Weninger, E, 2001) |
| "5-Aminolevulinic acid induced fluorescence endoscopy has outstanding sensitivity for detecting early stage bladder cancer." | 3.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "In 25 cases (53 biopsies) of a history of or suspicion for bladder cancer 5-aminolevulinic acid induced fluorescence endoscopy and fluorescence image quantification were performed." | 3.71 | Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. ( Baumgartner, R; Frimberger, D; Hofstetter, A; Knüchel, R; Kriegmair, M; Schneede, P; Siebels, M; Stepp, H; Wagner, S; Zaak, D, 2001) |
| "The safety and efficacy of treating individuals who presented with multiple actinic keratosis (AK) lesions with 5-aminolevulinic acid (ALA) in combination with photodynamic therapy (PDT) were documented in a phase III trial." | 3.71 | Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment. ( Fowler, JF; Zax, RH, 2002) |
| "To report clinical experience with intravesical instillations of 5-aminolevulinic acid (ALA) for the photodynamic therapy of superficial bladder cancer and to assess any side-effects of the treatment." | 3.69 | Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. ( Baumgartner, R; Hofstetter, A; Kriegmair, M; Lumper, W; Waidelich, R, 1996) |
| " Any adverse event occurring during/after ALA application/irradiation as well as pain intensity were recorded at each visit." | 2.94 | Efficacy and safety of conventional versus daylight photodynamic therapy in children affected by multiple facial flat warts. ( Borgia, F; Cannavò, SP; Coppola, M; Giuffrida, R; Guarneri, F; Princiotta, R; Vaccaro, M, 2020) |
| "ALA-PDT is effective and safe for FFWs, with striking cosmetic results and no recurrence." | 2.94 | Efficacy and safety of conventional versus daylight photodynamic therapy in children affected by multiple facial flat warts. ( Borgia, F; Cannavò, SP; Coppola, M; Giuffrida, R; Guarneri, F; Princiotta, R; Vaccaro, M, 2020) |
| " None of the 12 adverse events during surveillance were serious." | 2.87 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. ( Bivalacqua, T; Daneshmand, S; DeCastro, J; Downs, T; Huang, W; Jones, J; Jones, JS; Kamat, A; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, K; Resnick, M; Schoenberg, M; Steinberg, G; Trabulsi, E; Woods, M, 2018) |
| "Office based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and it is safe when used for surveillance." | 2.87 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. ( Bivalacqua, T; Daneshmand, S; DeCastro, J; Downs, T; Huang, W; Jones, J; Jones, JS; Kamat, A; Konety, B; Lotan, Y; O'Donnell, M; Patel, S; Pohar, K; Resnick, M; Schoenberg, M; Steinberg, G; Trabulsi, E; Woods, M, 2018) |
| "BACKGROUND Squamous cell carcinoma (SCC) is the second most common type of skin cancer, for which non- or mini-invasive treatment is of critical importance." | 2.84 | A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma. ( Dai, Y; Feng, W; Luo, X; Peng, J; Wang, T; Xiang, W; Zheng, J; Zhu, J, 2017) |
| "Diagnosis of bladder cancer is based on urine cytology and white-light cystoscopy (WLC) performed for patients with suspected bladder mass and÷or hematuria." | 2.84 | Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. ( Drăgoescu, NAM; Drăgoescu, PO; Drocaş, AI; Meşină, C; Mititelu, CD; Mitroi, G; Mohamed, G; Pănuş, A; Stănculescu, AD; Tomescu, PI; Tudorache, Ş, 2017) |
| "Patients with a history of bladder cancer were excluded." | 2.78 | Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi ( Chandra, A; Chatterton, K; Khan, MS; O'Brien, T; Ray, E; Thomas, K, 2013) |
| "Plaque-phase mycosis fungoides is among the most promising possibilities for the use of this treatment." | 2.75 | [Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients]. ( De Las Heras, E; Fernández-Guarino, M; Harto, A; Jaén, P; Montull, C; Pérez-García, B, 2010) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 2.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "Pain was assessed using a linear analogue scale from 0 to 10." | 2.70 | Photodynamic therapy for superficial bladder cancer under local anaesthetic. ( Betts, CD; Briggs, C; Clarke, NW; Gilhooley, A; Moore, JV; O'Flynn, KJ; Shackley, DC; Whitehurst, C, 2002) |
| "After a single treatment, 47 (85%) basal cell carcinomas showed a complete response at a follow-up time of at least 6 months." | 2.69 | Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. ( Hänggi, G; Hürlimann, AF; Panizzon, RG, 1998) |
| "5-Aminolevulinic acid (5-ALA) has been approved as an intraoperative adjunct in glioma surgery in Europe, but not North America." | 2.53 | The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. ( Bernstein, M; Hachem, LD; Klironomos, G; Mansouri, A; Mansouri, S; Vogelbaum, MA; Zadeh, G, 2016) |
| "Erythroplasia of Queyrat (EOQ) is a squamous cell carcinoma in situ most commonly located on the glans penis or prepuce." | 2.53 | Erythroplasia of Queyrat treated by laser and light modalities: a systematic review. ( Jimenez, JJ; Lim, VM; Maranda, EL; Nguyen, AH; Shah, VV, 2016) |
| "Surgical excision (SE) is a first-line treatment for basal cell carcinoma (BCC)." | 2.53 | Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. ( Han, J; Li, J; Lin, H; Luo, X; Ye, Z; Yu, J; Zhao, Y; Zou, Y, 2016) |
| "Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC)." | 2.50 | Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. ( Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Palou Redorta, J; Stenzl, A; van Velthoven, R; Witjes, JA; Zaak, D, 2014) |
| "In general, people with Bowen's disease have an excellent prognosis because the disease is typically slow-growing and responds favourably to treatment." | 2.49 | Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013) |
| "Bowen's disease is the clinical term for in situ squamous cell carcinoma of the skin." | 2.49 | Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013) |
| "Bladder cancer is the most common tumor of the urinary tract, with a worldwide incidence of 8." | 2.49 | Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over. ( Ambrosini, E; Frea, B; Giona, S; Gontero, P; Gurioli, A; Oderda, M; Peraldo, F; Soria, F, 2013) |
| "Residual tumour was significantly less often found after PDD (odds ratio: 0." | 2.46 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| "Although bladder cancer occurs frequently, early diagnosis and complete removal of malignant lesions usually lead to good clinical outcomes." | 2.45 | Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer. ( Kruck, S; Sievert, KD, 2009) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | 1.91 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "This study compared tumor recurrence among NMIBC patients who underwent TURBT under either white light cystoscopy (WL) or PDD." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence in NMIBC patients (cumulative number of recurrences/cumulative number of follow-up days, number of recurrences/10,000 days), including progression to muscle-invasive bladder cancer (MIBC), was 12." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "The frequency of recurrence was lower and the time to recurrence was longer in the PDD-TURBT group than in the WL-TURBT group." | 1.72 | Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT. ( Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kurabayashi, A; Lai, HW; Yamamoto, S, 2022) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 1.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Cervical high-grade squamous intraepithelial lesions (HSIL), as pre-cancerous lesions, have a 5% chance of progressing to invasive cancer." | 1.72 | The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions. ( Cao, L; Qin, L; Shen, Y; Su, Y; Tang, Y; Wang, B; Wang, L; Zhang, L; Zhang, M; Zhang, T; Zhang, Y; Zhou, Y, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 1.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| " We investigated the effects of aminolevulinic acid-based photodynamic therapy (ALA-PDT) combined with oral acitretin during therapy of refractory CA in the anal canal." | 1.72 | ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal. ( Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022) |
| " ALA-PDT group with 51 patients was given ALA-PDT treatment, and ALA-PDT plus acitretin group with 50 patients was given ALA-PDT treatment combined with oral acitretin." | 1.72 | ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal. ( Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022) |
| "ALA-PDT combined with oral acitretin is effective and safe in the treatment of refractory CA in anal canal, and with further study may become an option for these patients." | 1.72 | ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal. ( Chen, N; Cheng, Q; Lei, X; Li, J; Tang, H; Wu, J; Zeng, Q; Zhang, L, 2022) |
| " The adverse reactions after PDT were mild, mainly manifested as increased vaginal secretions or burning/tingling." | 1.72 | Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervical conization. ( Huang, Y; Jia, L; Liu, X; Liu, Y; Wang, L; Zhang, J; Zhang, Y, 2022) |
| "Complete neurosurgical resection of intracranial meningiomas is essential to avoid residual tumor tissue and thus minimize the risk of tumor recurrence." | 1.62 | High Diagnostic Accuracy of Visible 5-ALA Fluorescence in Meningioma Surgery According to Histopathological Analysis of Tumor Bulk and Peritumoral Tissue. ( Kiesel, B; Knosp, E; Makolli, J; Mercea, PA; Millesi, M; Mischkulnig, M; Roetzer, T; Rössler, K; Wadiura, LI; Wais, J; Widhalm, G, 2021) |
| "Glioblastoma is the most severe form of brain cancer." | 1.62 | Isolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy. ( Caputto, BL; Caverzán, MD; Milla Sanabria, LN; Palacios, RE; Prucca, CG; Rivarola, VA; Rodríguez, LB; Vilchez, ML, 2021) |
| " This study aimed to evaluate the efficacy and adverse effects of 5-aminolevulinic acid (ALA)-PDT in VEN treatment with a long-term follow-up." | 1.62 | Safety and effectiveness of 5-aminolevulinic acid photodynamic therapy combined with fractional micro-plasma radio-frequency treatment for verrucous epidermal nevus: A retrospective study with long-term follow-up. ( Chen, P; Dai, S; Guo, J; He, S; Huang, X; Li, Q; Shen, J; Zeng, K; Zhu, M, 2021) |
| "To evaluate the value of Wood's lamp examination combined with 5-aminolevulinic acid (5-ALA) photodynamic therapy (PDT) to determine positive tumor margins in patients with extramammary Paget's disease (EMPD) before surgery." | 1.62 | The application of Wood's lamp combined with 5-aminolevulinic acid for defining tumor margins in patients with extramammary Paget's disease. ( Fu, B; Li, J; Lou, Y; Song, C; Zhou, P, 2021) |
| " In the 5-ALA-PDT group, Wood's lamp examination combined with 5-ALA-PDT was used to trace the fluorescence range, and multipoint biopsy was performed according to the pathology to determine the final excision scope." | 1.62 | The application of Wood's lamp combined with 5-aminolevulinic acid for defining tumor margins in patients with extramammary Paget's disease. ( Fu, B; Li, J; Lou, Y; Song, C; Zhou, P, 2021) |
| "Wood's lamp examination combined with 5-ALA-PDT may predict tumor margins in EMPD." | 1.62 | The application of Wood's lamp combined with 5-aminolevulinic acid for defining tumor margins in patients with extramammary Paget's disease. ( Fu, B; Li, J; Lou, Y; Song, C; Zhou, P, 2021) |
| "Protoporphyrin IX (PpIX) is an endogenous photosensitizer (PS) widely used, obtained by the administration of precursors such as aminolevulinic acid and methyl aminolevulinate." | 1.56 | Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies. ( Bagnato, VS; Fortunato, TC; Pratavieira, S; Requena, MB; Russignoli, PE; Salvio, AG; Vollet-Filho, JD, 2020) |
| "This study was designed to compare the efficacy, the adverse effects and the costs of 10 % and 20 % ALA-PDT for AK treatment." | 1.56 | Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. ( Cao, Z; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, L; Zho, Z; Zhu, L, 2020) |
| "We reviewed the records of patients who had received ALA-PDT in our department between January 1, 2012, and April 30, 2017, the efficacy, the adverse effects were recorded, and the costs were analyzed." | 1.56 | Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. ( Cao, Z; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, L; Zho, Z; Zhu, L, 2020) |
| "A total of 59 AK patients' records were analyzed for the efficacy, the adverse events, the recurrence and the costs." | 1.56 | Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. ( Cao, Z; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, L; Zho, Z; Zhu, L, 2020) |
| "10 % ALA-PDT has similar efficacy and adverse effects as 20 % ALA-PDT with lower costs." | 1.56 | Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. ( Cao, Z; Shi, L; Wang, P; Wang, X; Zhang, G; Zhang, L; Zho, Z; Zhu, L, 2020) |
| "Anal canal condylomata acuminata is a disease caused by the human papilloma virus." | 1.56 | Advanced application of holmium: YAG laser combined ALA-PDT for the treatment of refractory condylomata acuminata in anal canal. ( Liao, C; Sun, X; Wang, X; Zhang, G; Zhang, H; Zhang, L, 2020) |
| "A total of six cases of ulcerative squamous cell carcinoma were included in our study." | 1.56 | Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for the treatment of ulcerative squamous cell carcinoma. ( Dong, L; Li, X; Lu, Y; Shen, X; Wang, Y; Zhang, J; Zhang, W, 2020) |
| "Bladder cancer is the eleventh most commonly diagnosed cancer worldwide." | 1.56 | Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis. ( Bracale, U; Buonopane, R; Califano, G; Capece, M; Creta, M; Crocetto, F; Di Meo, S; Fusco, F; Imbimbo, C; Imperatore, V; La Rocca, R; Longo, N; Mirone, V; Napolitano, L; Palmieri, A; Sodo, M; Spirito, L; Verze, P, 2020) |
| "The purpose of this study is to investigate the clinical efficacy of Mohs surgery in combination with topical photodynamic therapy (PDT) for facial basal cell carcinoma." | 1.56 | Clinical efficacy of Mohs surgery combined with topical photodynamic therapy for facial basal cell carcinoma. ( Kou, H; Lu, Y; Wang, Y; Yang, Y; Zhang, J; Zhang, X, 2020) |
| "The detection rate of HPV infections was 76." | 1.51 | Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment. ( Cai, Q; Chen, R; Han, P; Huang, X; Liang, F; Lin, P; Luo, M, 2019) |
| " The purpose of this article was to study the anti-tumor effect of ALA-PDT combined with limited excision in periocular basal cell carcinoma (BCC) and its role in improving the effect of the operation." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| "In our study, 8 patients with periocular basal cell carcinoma were treated with topical aminolevulinic acid photodynamic therapy (ALA-PDT) combined with surgery." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| "PDT in combination with limited surgery is a safe, effective and minimally-invasive approach for treating orbital BCC." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| "Superficial basal cell carcinoma is a type of keratinocyte carcinoma that has increasing incidence and substantial morbidity." | 1.48 | Comparing Topical Treatments for Basal Cell Carcinoma. ( Shaw, FM; Weinstock, MA, 2018) |
| "5-aminolevulinic acid (5-ALA) is a natural precursor of protoporphyrin IX (PP IX), which possesses fluorescent properties and is more intensively accumulated in tumor cells than in normal tissue." | 1.43 | Laser biospectroscopy and 5-ALA fluorescence navigation as a helpful tool in the meningioma resection. ( Chumakova, AP; Golbin, DA; Goldberg, MF; Goryaynov, SA; Loschenov, VB; Okhlopkov, VA; Potapov, AA; Savelieva, TA; Shishkina, LV; Spallone, A; Varyukhina, MD, 2016) |
| "Mean residual tumor volume (range) after iMRI-assisted surgery [0." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "Analysis of residual tumor volumes, total resections and neurological outcomes demonstrate that iMRI may be significantly superior to 5-ALA and white-light surgery for glioblastomas at comparable peri- and postoperative morbidities." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "RESULTS Recurrent bladder cancer was detected in 11 of the 32 (34%) examinations." | 1.36 | Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin. ( Chandra, A; Chatterton, K; Dasgupta, P; Khan, MS; O'Brien, TS; Ray, ER; Thomas, K, 2010) |
| "5-aminolevulinic acid (5-ALA) has gained importance as an intraoperative photodynamic diagnostic agent for the extirpation of malignant gliomas." | 1.36 | Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. ( Coluccia, D; Cordovi, S; Fandino, J; Fujioka, M; Landolt, H; Muroi, C, 2010) |
| "PDD during initial TUR-BT in T1G3 bladder cancer seems to reduce significantly the rate of recurrence in our study population." | 1.36 | Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. ( Karl, A; Knüchel, R; Stadler, T; Stanislaus, P; Stief, CG; Tritschler, S; Zaak, D, 2010) |
| "Five-aminolevulinic acid (ALA) is a drug which induces protoporphyrin IX accumulation in malignant gliomas and has been explored for fluorescence-guided resections of these tumors." | 1.35 | Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. ( Baumgartner, R; Beck, T; Beyer, W; Etminan, N; Herms, J; Kreth, FW; Mehrkens, JH; Obermeier, A; Stepp, H; Stummer, W; Tonn, JC, 2008) |
| "A total of 279 patients with suspected bladder tumors underwent transurethral resection using FD in addition to WL cystoscopy." | 1.31 | Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? ( Filbeck, T; Knuechel, R; Pichlmeier, U; Roessler, W; Wieland, WF, 2002) |
| "A total of 13 squamous cell carcinomas were treated, including 10 nasal planum lesions, two pinnal lesions and one eyelid lesion." | 1.31 | Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. ( Dobson, JM; Langmack, K; Stell, AJ, 2001) |
| "This was first shown for cancer of the bladder." | 1.31 | [Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier]. ( Zaak, D, 2002) |
| "The prognosis of superficial bladder cancer in terms of local recurrence and transformation into invasive cancer is related to the multiplicity of tumor sites and the concomitant presence of "flat" tumours, such as dysplasia and carcinoma in situ." | 1.30 | [The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder]. ( Forrer, M; Graber, P; Guillou, L; Jichlinski, P; Leisinger, HJ; Mizeret, J; Schmidlin, F; Van den Bergh, H; Wagniéres, G, 1997) |
| "Following transurethral resection of bladder cancer, the fate of patients is clearly related to the presence or absence of precancerous or malignant lesions in the remaining mucosa." | 1.29 | [Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid]. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (4.93) | 18.2507 |
| 2000's | 51 (25.12) | 29.6817 |
| 2010's | 81 (39.90) | 24.3611 |
| 2020's | 61 (30.05) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, T | 4 |
| Hu, R | 1 |
| Tang, Y | 3 |
| Zhang, Y | 5 |
| Qin, L | 3 |
| Shen, Y | 4 |
| Wang, B | 5 |
| Zhang, L | 8 |
| Cao, L | 3 |
| Zhou, Y | 4 |
| Su, Y | 4 |
| Zhang, M | 5 |
| Fukuhara, H | 2 |
| Yamamoto, S | 1 |
| Lai, HW | 1 |
| Karashima, T | 2 |
| Kurabayashi, A | 1 |
| Furihata, M | 2 |
| Inoue, K | 3 |
| Boschi, A | 1 |
| Lastrucci, G | 1 |
| Pisano, A | 1 |
| Becattini, E | 1 |
| Buccoliero, A | 1 |
| Della Puppa, A | 1 |
| Taoka, R | 1 |
| Matsuoka, Y | 1 |
| Yamasaki, M | 1 |
| Kani, N | 1 |
| Honda, T | 1 |
| Harada, S | 1 |
| Tohi, Y | 1 |
| Kato, T | 1 |
| Okazoe, H | 1 |
| Tsunemori, H | 1 |
| Ueda, N | 1 |
| Sugimoto, M | 1 |
| Wang, L | 2 |
| Werner, M | 1 |
| Lyu, C | 1 |
| Stadlbauer, B | 1 |
| Schrader, I | 1 |
| Buchner, A | 1 |
| Stepp, H | 8 |
| Sroka, R | 3 |
| Pohla, H | 1 |
| Zeng, Q | 2 |
| Li, J | 4 |
| Chen, N | 1 |
| Tang, H | 1 |
| Lei, X | 1 |
| Wu, J | 1 |
| Cheng, Q | 1 |
| Liu, X | 2 |
| Zhang, J | 5 |
| Huang, Y | 1 |
| Liu, Y | 1 |
| Jia, L | 2 |
| Omura, N | 1 |
| Nonoguchi, N | 1 |
| Fujishiro, T | 1 |
| Park, Y | 1 |
| Ikeda, N | 1 |
| Kajimoto, Y | 2 |
| Hosomi, R | 1 |
| Yagi, R | 1 |
| Hiramatsu, R | 1 |
| Furuse, M | 1 |
| Kawabata, S | 1 |
| Fukunaga, K | 1 |
| Kuroiwa, T | 2 |
| Nakano, I | 1 |
| Wanibuchi, M | 1 |
| Zhang, C | 1 |
| Zhou, M | 1 |
| Yuan, S | 1 |
| Shim, PJ | 3 |
| Zeitouni, NC | 3 |
| Zhao, H | 3 |
| Peng, P | 3 |
| Luo, Z | 3 |
| Liu, H | 3 |
| Sun, J | 4 |
| Wang, X | 9 |
| Jia, Q | 3 |
| Yang, Z | 3 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 2 |
| Bourgeois, P | 2 |
| Reyns, N | 3 |
| Lejeune, JP | 2 |
| Kobayashi, K | 1 |
| Matsuyama, H | 1 |
| Oka, S | 1 |
| Nakamura, K | 1 |
| Misumi, T | 1 |
| Hiroyoshi, T | 1 |
| Ito, H | 1 |
| Isoyama, N | 1 |
| Hirata, H | 1 |
| Matsumoto, H | 1 |
| Shiraishi, K | 1 |
| Bickels, J | 1 |
| Gortzak, Y | 1 |
| Sternheim, A | 1 |
| Hoogeveen, F | 1 |
| Blanker, MH | 1 |
| Cauberg, E | 1 |
| Steffens, MG | 1 |
| Liang, F | 1 |
| Han, P | 1 |
| Chen, R | 1 |
| Lin, P | 1 |
| Luo, M | 1 |
| Cai, Q | 1 |
| Huang, X | 2 |
| Yao, Y | 1 |
| Shen, X | 2 |
| Shi, L | 5 |
| Tang, G | 1 |
| Wu, L | 3 |
| Requena, MB | 2 |
| Russignoli, PE | 1 |
| Vollet-Filho, JD | 1 |
| Salvio, AG | 3 |
| Fortunato, TC | 1 |
| Pratavieira, S | 1 |
| Bagnato, VS | 4 |
| Zhang, G | 5 |
| Cao, Z | 1 |
| Wang, P | 4 |
| Zhu, L | 2 |
| Zho, Z | 1 |
| Drejer, D | 1 |
| Moltke, AL | 1 |
| Nielsen, AM | 1 |
| Lam, GW | 1 |
| Jensen, JB | 1 |
| Cai, H | 2 |
| Ma, T | 2 |
| Che, Y | 2 |
| Wang, Y | 5 |
| Wang, C | 1 |
| Yin, G | 1 |
| Radakovic, S | 1 |
| Dangl, M | 1 |
| Tanew, A | 1 |
| Logan, IT | 1 |
| Kulakov, EL | 1 |
| Perrett, CM | 1 |
| Chaabani, M | 1 |
| Ben Lagha, I | 1 |
| Ben Tanfous, A | 1 |
| Koubaa, W | 1 |
| Ben Brahim, E | 1 |
| Fenniche, S | 1 |
| Zaouak, A | 1 |
| Hammami-Ghorbel, H | 1 |
| La Rocca, G | 1 |
| Sabatino, G | 1 |
| Menna, G | 1 |
| Altieri, R | 2 |
| Ius, T | 1 |
| Marchese, E | 1 |
| Olivi, A | 1 |
| Barresi, V | 1 |
| Della Pepa, GM | 1 |
| Liao, C | 2 |
| Sun, X | 2 |
| Zhang, H | 1 |
| Stringasci, MD | 3 |
| Barreto Requena, M | 1 |
| Dong, L | 1 |
| Li, X | 4 |
| Zhang, W | 1 |
| Lu, Y | 5 |
| Pohar, KS | 1 |
| Capece, M | 1 |
| Spirito, L | 1 |
| La Rocca, R | 1 |
| Napolitano, L | 1 |
| Buonopane, R | 1 |
| Di Meo, S | 1 |
| Sodo, M | 1 |
| Bracale, U | 1 |
| Longo, N | 1 |
| Palmieri, A | 1 |
| Fusco, F | 1 |
| Verze, P | 1 |
| Califano, G | 1 |
| Crocetto, F | 1 |
| Imbimbo, C | 1 |
| Mirone, V | 1 |
| Imperatore, V | 1 |
| Creta, M | 1 |
| Warsi, NM | 1 |
| Zewude, R | 1 |
| Karmur, B | 1 |
| Pirouzmand, N | 1 |
| Hachem, L | 1 |
| Mansouri, A | 2 |
| Broekx, S | 1 |
| Weyns, F | 1 |
| De Vleeschouwer, S | 1 |
| Borgia, F | 1 |
| Giuffrida, R | 1 |
| Coppola, M | 1 |
| Princiotta, R | 1 |
| Vaccaro, M | 1 |
| Guarneri, F | 1 |
| Cannavò, SP | 1 |
| Yan, L | 1 |
| Ding, Z | 1 |
| Sun, H | 1 |
| Wadiura, LI | 1 |
| Millesi, M | 1 |
| Makolli, J | 1 |
| Wais, J | 1 |
| Kiesel, B | 1 |
| Mischkulnig, M | 1 |
| Mercea, PA | 1 |
| Roetzer, T | 1 |
| Knosp, E | 1 |
| Rössler, K | 1 |
| Widhalm, G | 1 |
| Lotan, Y | 5 |
| Chaplin, I | 1 |
| Ahmadi, H | 1 |
| Meng, X | 1 |
| Roberts, S | 1 |
| Ladi-Seyedian, S | 1 |
| Bagrodia, A | 1 |
| Margulis, V | 1 |
| Woldu, S | 1 |
| Daneshmand, S | 3 |
| de Castro, CA | 1 |
| Lombardi, W | 1 |
| Inada, NM | 1 |
| Zhang, GL | 1 |
| Keyal, U | 1 |
| Wang, PR | 1 |
| Zhang, LL | 1 |
| Bhatta, AK | 1 |
| Wu, YH | 1 |
| Fang, S | 1 |
| Wang, XL | 1 |
| Kremer, N | 1 |
| Sherman, S | 1 |
| Lapidoth, M | 1 |
| Enk, CD | 1 |
| Leshem, YA | 1 |
| Mimouni, T | 1 |
| Dudkiewicz, D | 1 |
| Hodak, E | 1 |
| Levi, A | 1 |
| Zhang, X | 3 |
| Yang, Y | 4 |
| Kou, H | 3 |
| Mizuno, M | 1 |
| Mitsui, H | 1 |
| Kajiyama, H | 1 |
| Teshigawara, T | 1 |
| Takahashi, K | 1 |
| Ishii, T | 1 |
| Ishizuka, M | 1 |
| Nakajima, M | 1 |
| Kikkawa, F | 1 |
| Thomson, J | 1 |
| Hogan, S | 1 |
| Leonardi-Bee, J | 2 |
| Williams, HC | 1 |
| Bath-Hextall, FJ | 2 |
| Vilchez, ML | 1 |
| Rodríguez, LB | 1 |
| Palacios, RE | 1 |
| Prucca, CG | 1 |
| Caverzán, MD | 1 |
| Caputto, BL | 1 |
| Rivarola, VA | 1 |
| Milla Sanabria, LN | 1 |
| Barbagallo, GMV | 1 |
| Certo, F | 1 |
| Di Gregorio, S | 1 |
| Maione, M | 1 |
| Garozzo, M | 1 |
| Peschillo, S | 1 |
| Liu, D | 1 |
| Zhao, S | 2 |
| Chen, M | 2 |
| Zhao, Z | 1 |
| Zhou, Z | 2 |
| Gracia-Cazaña, T | 1 |
| Nicolás, J | 1 |
| Cerro-Muñoz, PA | 1 |
| González, S | 2 |
| Juarranz, Á | 1 |
| Gilaberte, Y | 1 |
| Kechichian, E | 1 |
| Helou, E | 1 |
| Sarkis, J | 1 |
| Hayek, C | 1 |
| Labaki, C | 1 |
| Nemr, E | 1 |
| Tomb, R | 1 |
| Todenhöfer, T | 1 |
| Maas, M | 1 |
| Ketz, M | 1 |
| Kossack, N | 1 |
| Colling, C | 1 |
| Qvick, B | 1 |
| Stenzl, A | 8 |
| Ma, X | 1 |
| Shen, H | 1 |
| Liu, B | 1 |
| Tan, L | 3 |
| Huang, J | 1 |
| Tang, Z | 1 |
| Tong, X | 1 |
| Gao, L | 1 |
| Zeng, J | 1 |
| Dai, S | 1 |
| He, S | 1 |
| Chen, P | 1 |
| Li, Q | 2 |
| Guo, J | 1 |
| Zhu, M | 1 |
| Shen, J | 1 |
| Zeng, K | 1 |
| Sugino, Y | 1 |
| Nishikawa, K | 1 |
| Kato, M | 2 |
| Sasaki, T | 1 |
| Masui, S | 1 |
| Yoshio, Y | 1 |
| Kanda, H | 1 |
| Sugimura, Y | 1 |
| Inoue, T | 1 |
| Leroy, HA | 1 |
| Guérin, L | 1 |
| Lecomte, F | 1 |
| Baert, G | 1 |
| Vignion, AS | 1 |
| Mordon, S | 1 |
| Zhou, P | 1 |
| Song, C | 1 |
| Lou, Y | 1 |
| Fu, B | 1 |
| Peng, J | 1 |
| Feng, W | 1 |
| Luo, X | 2 |
| Wang, T | 1 |
| Xiang, W | 1 |
| Dai, Y | 1 |
| Zhu, J | 1 |
| Zheng, J | 1 |
| Teixeira, AI | 1 |
| Maia E Silva, J | 1 |
| Jacqmin, D | 4 |
| Jichlinski, P | 5 |
| Molinier, L | 1 |
| de la Taille, A | 1 |
| Irani, J | 1 |
| Malavaud, B | 1 |
| Gallagher, KM | 1 |
| Gray, K | 1 |
| Anderson, CH | 1 |
| Lee, H | 1 |
| Stewart, S | 1 |
| Donat, R | 1 |
| Mariappan, P | 2 |
| Ross, JL | 1 |
| Cooper, LAD | 1 |
| Kong, J | 1 |
| Gutman, D | 1 |
| Williams, M | 1 |
| Tucker-Burden, C | 1 |
| McCrary, MR | 1 |
| Bouras, A | 1 |
| Kaluzova, M | 1 |
| Dunn, WD | 1 |
| Duong, D | 1 |
| Hadjipanayis, CG | 1 |
| Brat, DJ | 1 |
| Kohoutova, D | 1 |
| Haidry, R | 1 |
| Banks, M | 1 |
| Butt, MA | 1 |
| Dunn, J | 1 |
| Thorpe, S | 1 |
| Lovat, L | 1 |
| Patel, S | 2 |
| Pohar, K | 2 |
| Trabulsi, E | 2 |
| Woods, M | 2 |
| Downs, T | 2 |
| Huang, W | 2 |
| Jones, J | 2 |
| O'Donnell, M | 2 |
| Bivalacqua, T | 2 |
| DeCastro, J | 2 |
| Steinberg, G | 3 |
| Kamat, A | 2 |
| Resnick, M | 2 |
| Konety, B | 2 |
| Schoenberg, M | 2 |
| Jones, JS | 2 |
| Zhang, S | 1 |
| Yang, L | 1 |
| Yu, R | 1 |
| Hu, N | 1 |
| Shaw, FM | 1 |
| Weinstock, MA | 1 |
| Drăgoescu, PO | 1 |
| Tudorache, Ş | 1 |
| Drocaş, AI | 1 |
| Mitroi, G | 1 |
| Pănuş, A | 1 |
| Drăgoescu, NAM | 1 |
| Meşină, C | 1 |
| Mititelu, CD | 1 |
| Stănculescu, AD | 1 |
| Mohamed, G | 1 |
| Tomescu, PI | 1 |
| Feng, H | 1 |
| Li, F | 2 |
| Kim, HJ | 1 |
| Song, KH | 2 |
| Rioli, DI | 1 |
| Samimi, M | 1 |
| Beneton, N | 1 |
| Hainaut, E | 1 |
| Martin, L | 1 |
| Misery, L | 1 |
| Quereux, G | 1 |
| Smith, AB | 1 |
| Taylor, J | 1 |
| Chohan, MO | 1 |
| Berger, MS | 3 |
| He, X | 2 |
| Wang, W | 2 |
| Song, Y | 2 |
| Wang, H | 1 |
| Kamp, MA | 2 |
| Munoz-Bendix, C | 1 |
| Mijderwijk, HJ | 1 |
| Turowski, B | 1 |
| Dibué-Adjei, M | 1 |
| von Saß, C | 1 |
| Cornelius, JF | 1 |
| Steiger, HJ | 2 |
| Rapp, M | 2 |
| Sabel, M | 2 |
| Doglietto, F | 1 |
| Belotti, F | 1 |
| Panciani, P | 1 |
| Poliani, PL | 1 |
| Fontanella, MM | 1 |
| Li, G | 2 |
| Shi, W | 1 |
| Su, J | 1 |
| Chen, X | 1 |
| Cage, TA | 1 |
| Pekmezci, M | 1 |
| Prados, M | 1 |
| Prat-Acín, R | 1 |
| Galeano-Senabre, I | 1 |
| Pancucci, G | 1 |
| Evangelista, R | 1 |
| Ayuso-Sacido, A | 1 |
| Botella, C | 1 |
| Roozeboom, MH | 1 |
| Aardoom, MA | 1 |
| Nelemans, PJ | 1 |
| Thissen, MR | 1 |
| Kelleners-Smeets, NW | 1 |
| Kuijpers, DI | 1 |
| Mosterd, K | 2 |
| Burger, M | 5 |
| Grossman, HB | 3 |
| Droller, M | 1 |
| Schmidbauer, J | 1 |
| Hermann, G | 1 |
| Drăgoescu, O | 1 |
| Ray, E | 2 |
| Fradet, Y | 3 |
| Karl, A | 5 |
| Burgués, JP | 1 |
| Witjes, JA | 5 |
| Jocham, D | 4 |
| Lippert, J | 1 |
| Smucler, R | 1 |
| Vlk, M | 1 |
| Tejada-Solis, S | 1 |
| Díez-Valle, R | 1 |
| Matin, RN | 1 |
| Wilkinson, D | 1 |
| Soria, F | 1 |
| Gurioli, A | 1 |
| Peraldo, F | 1 |
| Oderda, M | 1 |
| Giona, S | 1 |
| Ambrosini, E | 1 |
| Frea, B | 1 |
| Gontero, P | 2 |
| O'Brien, T | 2 |
| Chatterton, K | 2 |
| Khan, MS | 2 |
| Chandra, A | 2 |
| Thomas, K | 3 |
| Ko, DY | 1 |
| Kim, KH | 1 |
| Yang, LP | 1 |
| Gkritsios, P | 1 |
| Hatzimouratidis, K | 1 |
| Kazantzidis, S | 1 |
| Dimitriadis, G | 1 |
| Ioannidis, E | 1 |
| Katsikas, V | 1 |
| Themstrup, L | 1 |
| Banzhaf, CA | 1 |
| Mogensen, M | 1 |
| Jemec, GB | 1 |
| Roder, C | 1 |
| Bisdas, S | 1 |
| Ebner, FH | 1 |
| Honegger, J | 1 |
| Naegele, T | 1 |
| Ernemann, U | 1 |
| Tatagiba, M | 1 |
| Jing, W | 1 |
| Juan, X | 1 |
| Jiayuan, C | 1 |
| Qin, H | 1 |
| Qing, L | 1 |
| Shengmei, X | 1 |
| Haak, CS | 1 |
| Togsverd-Bo, K | 1 |
| Thaysen-Petersen, D | 1 |
| Wulf, HC | 2 |
| Paasch, U | 1 |
| Anderson, RR | 1 |
| Haedersdal, M | 1 |
| Babjuk, M | 4 |
| Kruck, S | 2 |
| Palou Redorta, J | 1 |
| van Velthoven, R | 1 |
| Zaak, D | 10 |
| Sun, IS | 1 |
| Kirollos, R | 1 |
| Santarius, T | 1 |
| Felsberg, J | 1 |
| Sadat, H | 1 |
| Kuzibaev, J | 1 |
| Reifenberger, G | 1 |
| Dibué, M | 1 |
| Hickmann, AK | 1 |
| Nadji-Ohl, M | 1 |
| Hopf, NJ | 1 |
| Rose, JB | 1 |
| Armstrong, S | 1 |
| Hermann, GG | 1 |
| Kjellberg, J | 1 |
| Malmström, PU | 2 |
| Lau, D | 1 |
| Hervey-Jumper, SL | 1 |
| Chang, S | 1 |
| Molinaro, AM | 1 |
| McDermott, MW | 1 |
| Phillips, JJ | 1 |
| Kessels, J | 1 |
| Hendriks, J | 1 |
| Nelemans, P | 1 |
| Kelleners-Smeets, N | 1 |
| Potapov, AA | 1 |
| Goryaynov, SA | 1 |
| Okhlopkov, VA | 1 |
| Shishkina, LV | 1 |
| Loschenov, VB | 1 |
| Savelieva, TA | 1 |
| Golbin, DA | 1 |
| Chumakova, AP | 1 |
| Goldberg, MF | 1 |
| Varyukhina, MD | 1 |
| Spallone, A | 1 |
| Mansouri, S | 1 |
| Hachem, LD | 1 |
| Klironomos, G | 1 |
| Vogelbaum, MA | 1 |
| Bernstein, M | 1 |
| Zadeh, G | 1 |
| Maranda, EL | 1 |
| Nguyen, AH | 1 |
| Lim, VM | 1 |
| Shah, VV | 1 |
| Jimenez, JJ | 1 |
| Zou, Y | 1 |
| Zhao, Y | 1 |
| Yu, J | 1 |
| Han, J | 1 |
| Ye, Z | 1 |
| Lin, H | 1 |
| Rolevich, AI | 2 |
| Zhegalik, AG | 1 |
| Mokhort, AA | 1 |
| Minich, AA | 1 |
| Vasilevich, VY | 1 |
| Polyakov, SL | 1 |
| Krasny, SA | 1 |
| Sukonko, OG | 1 |
| Suárez Valladares, MJ | 1 |
| Pérez Paredes, MG | 1 |
| González Sixto, B | 1 |
| Rodríguez Prieto, MÁ | 1 |
| Zeng, Y | 1 |
| Gao, Y | 1 |
| Evmenenko, AA | 1 |
| Adam, C | 1 |
| Salomon, G | 1 |
| Walther, S | 1 |
| Khoder, W | 1 |
| Becker, A | 1 |
| Reich, O | 1 |
| Blana, A | 1 |
| Ganzer, R | 1 |
| Denzinger, S | 3 |
| Popken, G | 1 |
| Knüchel-Clarke, R | 1 |
| Köllermann, J | 1 |
| Sauter, G | 1 |
| Hartmann, A | 2 |
| Bertz, S | 1 |
| Graefen, M | 1 |
| Huland, H | 1 |
| Wieland, W | 1 |
| Stief, CG | 4 |
| Fai, D | 1 |
| Arpaia, N | 1 |
| Romano, I | 1 |
| Vestita, M | 1 |
| Cassano, N | 1 |
| Vena, GA | 1 |
| Mostafid, H | 2 |
| Bunce, C | 2 |
| Mougel, F | 1 |
| Debarbieux, S | 1 |
| Ronger-Savlé, S | 1 |
| Dalle, S | 1 |
| Thomas, L | 1 |
| Sievert, KD | 1 |
| Wieland, WF | 5 |
| Otto, W | 1 |
| Ray, ER | 1 |
| Dasgupta, P | 1 |
| O'Brien, TS | 1 |
| Scarpa, RM | 1 |
| Cracco, CM | 1 |
| Kuno, T | 1 |
| Hamaguchi, T | 1 |
| Fukata, S | 1 |
| Kamada, M | 1 |
| Shuin, T | 1 |
| Sakakura, N | 1 |
| Kasahara, K | 1 |
| Watanabe, H | 1 |
| Kozai, T | 1 |
| Yasuda, M | 1 |
| Kataoka, S | 1 |
| Tanimura, M | 1 |
| Atsushi, K | 1 |
| Kausch, I | 1 |
| Sommerauer, M | 1 |
| Montorsi, F | 2 |
| Ziegler, A | 1 |
| Vonthein, R | 1 |
| Ayres, BE | 1 |
| Griffiths, TR | 1 |
| Kelly, J | 1 |
| Persad, R | 1 |
| Kockelbergh, R | 1 |
| Redorta, JP | 1 |
| Sofras, F | 1 |
| Riedl, C | 2 |
| Conti, G | 1 |
| Arentsen, HC | 1 |
| Mostafid, AH | 1 |
| Coluccia, D | 1 |
| Fandino, J | 1 |
| Fujioka, M | 1 |
| Cordovi, S | 1 |
| Muroi, C | 1 |
| Landolt, H | 1 |
| Stanislaus, P | 1 |
| Stadler, T | 1 |
| Tritschler, S | 1 |
| Knüchel, R | 3 |
| Geavlete, B | 2 |
| Jecu, M | 2 |
| Multescu, R | 2 |
| Georgescu, D | 2 |
| Geavlete, P | 2 |
| Mynderse, LA | 2 |
| Soloway, MS | 2 |
| Kriegmair, M | 8 |
| Fernández-Guarino, M | 1 |
| Harto, A | 1 |
| Pérez-García, B | 1 |
| Montull, C | 1 |
| De Las Heras, E | 1 |
| Jaén, P | 1 |
| Kostron, H | 1 |
| Bauer, R | 1 |
| Whitson, WJ | 1 |
| Valdes, PA | 1 |
| Harris, BT | 1 |
| Paulsen, KD | 1 |
| Roberts, DW | 1 |
| Gao, T | 1 |
| Jiao, B | 1 |
| Hu, X | 1 |
| Luan, Q | 1 |
| Li, K | 1 |
| Ma, C | 1 |
| Li, C | 1 |
| Wang, S | 1 |
| Stanescu, F | 1 |
| Cavicchini, S | 1 |
| Serini, SM | 1 |
| Fiorani, R | 1 |
| Girgenti, V | 1 |
| Ghislanzoni, M | 1 |
| Sala, F | 1 |
| Lindberg-Larsen, R | 1 |
| Sølvsten, H | 1 |
| Kragballe, K | 1 |
| Osiecka, B | 1 |
| Jurczyszyn, K | 1 |
| Ziółkowski, P | 1 |
| Christensen, E | 1 |
| Mørk, C | 1 |
| Skogvoll, E | 1 |
| Requena, C | 1 |
| Messeguer, F | 1 |
| Llombart, B | 1 |
| Serra-Guillén, C | 1 |
| Guillén, C | 1 |
| Bader, MJ | 1 |
| Beyer, W | 4 |
| Pongratz, T | 1 |
| Welschof, M | 1 |
| Tilki, D | 1 |
| Waidelich, R | 5 |
| Sagalowsky, AI | 1 |
| Wachter, D | 1 |
| Kallenberg, K | 1 |
| Wrede, A | 1 |
| Schulz-Schaeffer, W | 1 |
| Behm, T | 1 |
| Rohde, V | 1 |
| Meng, MV | 1 |
| Karaolides, T | 1 |
| Skolarikos, A | 1 |
| Bourdoumis, A | 1 |
| Konandreas, A | 1 |
| Mygdalis, V | 1 |
| Thanos, A | 1 |
| Deliveliotis, C | 1 |
| Venturini, M | 1 |
| Sala, R | 1 |
| Calzavara-Pinton, PG | 1 |
| Wiegell, SR | 1 |
| Skødt, V | 1 |
| Filbeck, T | 4 |
| Pichlmeier, U | 2 |
| Knuechel, R | 5 |
| Roessler, W | 3 |
| Baumgartner, R | 9 |
| Schneede, P | 2 |
| Frimberger, D | 2 |
| Künchel, R | 1 |
| Hofstetter, A | 6 |
| Hohla, A | 1 |
| Berger, AP | 1 |
| Steiner, H | 1 |
| Akkad, T | 1 |
| Bartsch, G | 1 |
| Holtl, L | 1 |
| Madsen, SJ | 1 |
| Sun, CH | 1 |
| Tromberg, BJ | 1 |
| Hirschberg, H | 1 |
| Marti, A | 1 |
| Lange, N | 1 |
| Ballini, JP | 1 |
| Guillou, L | 2 |
| Leisinger, HJ | 2 |
| Kucera, P | 1 |
| Clark, C | 1 |
| Bryden, A | 1 |
| Dawe, R | 1 |
| Moseley, H | 2 |
| Ferguson, J | 2 |
| Ibbotson, SH | 1 |
| Rössler, W | 1 |
| Marmur, ES | 1 |
| Schmults, CD | 1 |
| Goldberg, DJ | 1 |
| Naidenov, N | 1 |
| Dencheva, R | 1 |
| Tsankov, N | 1 |
| Daniltchenko, D | 2 |
| Koenig, F | 3 |
| Daha, LK | 1 |
| Sachs, M | 1 |
| Schnorr, D | 2 |
| Skyrme, RJ | 1 |
| French, AJ | 1 |
| Datta, SN | 1 |
| Allman, R | 1 |
| Mason, MD | 1 |
| Matthews, PN | 1 |
| Mikasa, K | 1 |
| Watanabe, D | 2 |
| Kondo, C | 1 |
| Kobayashi, M | 1 |
| Nakaseko, H | 1 |
| Yokoo, K | 1 |
| Tamada, Y | 2 |
| Matsumoto, Y | 2 |
| Senior, K | 1 |
| Soukup, V | 2 |
| Petrík, R | 3 |
| Jirsa, M | 3 |
| Dvorácek, J | 2 |
| Hillemanns, P | 1 |
| Staehle, S | 1 |
| Michels, W | 1 |
| Dannecker, C | 1 |
| Pavlík, I | 1 |
| Pecen, L | 1 |
| Daniltchenko, DI | 1 |
| Riedl, CR | 2 |
| Sachs, MD | 1 |
| Daha, KL | 1 |
| Pflueger, H | 2 |
| Loening, SA | 2 |
| Ibbotson, S | 1 |
| Woods, J | 1 |
| Brancaleon, L | 1 |
| Lesar, A | 1 |
| Goodman, C | 1 |
| Raspagliesi, F | 1 |
| Fontanelli, R | 1 |
| Rossi, G | 1 |
| Ditto, A | 1 |
| Solima, E | 1 |
| Hanozet, F | 1 |
| Kusamura, S | 1 |
| Walter, B | 1 |
| Franco, RA | 1 |
| Miyatake, S | 1 |
| Ichioka, T | 1 |
| Miyashita, M | 1 |
| Tanaka, H | 1 |
| Tsuji, M | 1 |
| Beck, TJ | 1 |
| Kreth, FW | 2 |
| Mehrkens, JH | 2 |
| Obermeier, A | 2 |
| Stummer, W | 2 |
| Rhodes, LE | 1 |
| de Rie, MA | 1 |
| Leifsdottir, R | 1 |
| Yu, RC | 1 |
| Bachmann, I | 1 |
| Goulden, V | 1 |
| Wong, GA | 1 |
| Richard, MA | 1 |
| Anstey, A | 1 |
| Wolf, P | 1 |
| L'eplattenier, HF | 1 |
| Klem, B | 1 |
| Teske, E | 1 |
| van Sluijs, FJ | 1 |
| van Nimwegen, SA | 1 |
| Kirpensteijn, J | 1 |
| Forster, TH | 1 |
| Wyler, S | 1 |
| Ruszat, R | 1 |
| Gasser, TC | 1 |
| Bachmann, A | 1 |
| Beck, T | 1 |
| Etminan, N | 1 |
| Tonn, JC | 1 |
| Herms, J | 1 |
| Kuhara, T | 1 |
| Akita, Y | 1 |
| Takeo, T | 1 |
| Ishida, N | 1 |
| Nakano, A | 1 |
| Yamashita, N | 1 |
| Ohshima, Y | 1 |
| Kawada, M | 1 |
| Yanagishita, T | 1 |
| Karrer, S | 1 |
| Szeimies, RM | 1 |
| Hohenleutner, U | 1 |
| Heine, A | 1 |
| Landthaler, M | 1 |
| Korell, M | 1 |
| Untch, M | 1 |
| Abels, C | 1 |
| Dellian, M | 1 |
| Kirschstein, M | 1 |
| Goetz, AE | 1 |
| van Hillegersberg, R | 1 |
| Hekking-Weijma, JM | 1 |
| Wilson, JH | 1 |
| Edixhoven-Bosdijk, A | 1 |
| Kort, WJ | 1 |
| Ehsan, A | 1 |
| Steinbach, P | 1 |
| Lumper, W | 2 |
| Hofstädter, F | 1 |
| Wagniéres, G | 1 |
| Forrer, M | 1 |
| Mizeret, J | 1 |
| Schmidlin, F | 1 |
| Graber, P | 1 |
| Van den Bergh, H | 1 |
| Hürlimann, AF | 1 |
| Hänggi, G | 1 |
| Panizzon, RG | 1 |
| Dvorák, E | 1 |
| Skoda, V | 1 |
| Stádník, B | 1 |
| Straub, M | 1 |
| Kiel, HJ | 1 |
| Morton, CA | 2 |
| Whitehurst, C | 3 |
| Moore, JV | 3 |
| MacKie, RM | 2 |
| Soler, AM | 2 |
| Warloe, T | 2 |
| Tausjø, J | 1 |
| Giercksky, KE | 2 |
| McColl, JH | 1 |
| Simak, R | 1 |
| Stell, AJ | 1 |
| Dobson, JM | 1 |
| Langmack, K | 1 |
| Weninger, E | 1 |
| Berner, A | 1 |
| Wagner, S | 1 |
| Siebels, M | 1 |
| Sieron, A | 1 |
| Namyslowski, G | 1 |
| Misiolek, M | 1 |
| Adamek, M | 1 |
| Kawczyk-Krupka, A | 1 |
| Shackley, DC | 1 |
| Briggs, C | 1 |
| Gilhooley, A | 1 |
| O'Flynn, KJ | 1 |
| Betts, CD | 1 |
| Clarke, NW | 1 |
| Lipinski, M | 1 |
| Jeromin, L | 1 |
| Fowler, JF | 1 |
| Zax, RH | 1 |
| Labuschagne, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blue Light Cystoscopy With Cysview® Registry[NCT02660645] | 4,400 participants (Anticipated) | Observational [Patient Registry] | 2014-04-30 | Recruiting | |||
| A Prospective, Open, Comparative, Within Patient Controlled Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients Wit[NCT02560584] | Phase 3 | 304 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial[NCT03909646] | Phase 4 | 250 participants (Anticipated) | Interventional | 2019-05-27 | Recruiting | ||
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas[NCT05850377] | 90 participants (Anticipated) | Observational | 2023-06-01 | Not yet recruiting | |||
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)[NCT04186013] | Phase 2 | 39 participants (Anticipated) | Interventional | 2019-09-18 | Active, not recruiting | ||
| A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer[NCT00233402] | Phase 3 | 789 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Surveillance Examination | 6 |
| Surveillance + OR Examination | 3 |
In the subsection of patients with histologically confirmed malignancy, the proportion of patients detected only by the use of blue light cystoscopy with Cysview is measured. (NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Cysview Arm | 13 |
In the subsection of patients with histologically confirmed CIS, the proportion of patients detected only by blue light cystoscopy with Cysview is measured. (NCT02560584)
Timeframe: At time of cystoscopy procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Cysview Arm | 9 |
(NCT00233402)
Timeframe: 9 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Group | 47.2 |
| White Light Group | 56.1 |
"The false detection rate for Hexvix cystoscopy was calculated as the total number of false positive lesions (i.e. lesions that were suspected with blue light but had negative histology according to the Standard of Truth central panel read) divided by the total number of lesions that were suspected with blue light (i.e., false positive divided by false positive plus true positive).~The corresponding false detection rates were also calculated for white light cystoscopy for the two groups separately." (NCT00233402)
Timeframe: Day 0
| Intervention | Percetange of lesion (Number) |
|---|---|
| Hexvix Group | 12 |
| White Light Group | 10 |
(NCT00233402)
Timeframe: Day 0
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Group | 16.4 |
(NCT00233402)
Timeframe: Day 0
| Intervention | percentage of participants (Number) |
|---|---|
| Hexvix Fluorescence Cystoscopy | 31.7 |
29 reviews available for aminolevulinic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnostic Errors; False Positive | 2020 |
Blue Light Cystoscopy: Indications and Outcomes.
Topics: Administration, Intravesical; Aminolevulinic Acid; Cystoscopy; Disease Progression; Humans; Light; N | 2020 |
The Cost-Effectiveness of 5-ALA in High-Grade Glioma Surgery: A Quality-Based Systematic Review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Canada; Cost-Benefit Analysis; Glioma; Humans; Neoplasm Recurr | 2020 |
5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Neuronavigation; N | 2020 |
Interventions for basal cell carcinoma of the skin.
Topics: Adult; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Cryotherapy; Female; Human | 2020 |
The application of physical pretreatment in photodynamic therapy for skin diseases.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Neoplasm Recurrence, Local; Photochemotherapy; Phot | 2021 |
The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic review.
Topics: Aminolevulinic Acid; Humans; Neoplasm Recurrence, Local; Papillomavirus Infections; Photochemotherap | 2021 |
Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Topics: Aminolevulinic Acid; China; Cystoscopy; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photo | 2021 |
Is interstitial photodynamic therapy for brain tumors ready for clinical practice? A systematic review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photose | 2021 |
[Progression of basic research, clinical application of photodynamic therapy and fluorescence-guided surgery in glioma treatment].
Topics: Aminolevulinic Acid; Biomedical Research; Brain Neoplasms; Chemotherapy, Adjuvant; Fluorescence; Gli | 2018 |
5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescent Dyes; Glioma; Humans; Neoplasm Grading; Neoplasm R | 2019 |
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Humans; Kaplan-Meier Estimate; Neoplasm Invasive | 2013 |
Interventions for cutaneous Bowen's disease.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Cryotherapy; Fluoroura | 2013 |
Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; False Negative Rea | 2013 |
Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Cystoscopy; Humans; Meta-Analysis as Topic; Microscop | 2014 |
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease Progression; Disease-Fre | 2014 |
The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioma; Humans; Intraoperative Care; Magnetic Resonance Imagin | 2016 |
Erythroplasia of Queyrat treated by laser and light modalities: a systematic review.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Lasers, Gas; Lasers, Solid-State; Low-Level L | 2016 |
Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy; P | 2016 |
[A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resect
Topics: Aminolevulinic Acid; Cystectomy; Disease-Free Survival; Humans; Neoplasm Recurrence, Local; Photosen | 2016 |
Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Cystoscopy; Fluorescent Dyes; Humans; Neoplasm Recurr | 2009 |
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Photosen | 2010 |
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
Management of recurrent malignant glioma--neurosurgical strategies.
Topics: Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Microscopy, F | 2011 |
A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Ker | 2004 |
["... The better to see you with"--phothodynamic diagnostic in superficial bladder cancer].
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Carcinoma in Situ; Carcinoma, Papillary; | 2007 |
[Fluorescence diagnosis and photodynamic therapy in urology].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II | 2007 |
44 trials available for aminolevulinic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Humans; Image Enhancement; Male; N | 2020 |
Efficacy and safety of conventional versus daylight photodynamic therapy in children affected by multiple facial flat warts.
Topics: Aged; Aminolevulinic Acid; Child; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photosensit | 2020 |
A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma.
Topics: Aged; Aminolevulinic Acid; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; H | 2017 |
Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett's oesophagus related neoplasia.
Topics: Adenocarcinoma; Adult; Aged; Aminolevulinic Acid; Barrett Esophagus; Catheter Ablation; Dihematoporp | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Middle Aged; | 2018 |
Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Topics: Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ph | 2017 |
Ablative fractional laser-assisted photodynamic therapy provides superior long-term efficacy compared with standard methyl aminolevulinate photodynamic therapy for lower extremity Bowen disease.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy, Needle; Bowen's Disease; Combined Modality The | 2018 |
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.
Topics: Aged; Aminolevulinic Acid; Anxiety; Color; Cystoscopy; False Positive Reactions; Female; Fluorescent | 2019 |
Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap | 2013 |
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2013 |
A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Asian People; Bowen's Disease; Female; Follow-U | 2014 |
Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
Topics: Aged; Aminolevulinic Acid; Color; Contrast Media; Cystoscopy; Disease-Free Survival; False Positive | 2014 |
Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosi | 2014 |
Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap | 2015 |
A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.
Topics: Aminolevulinic Acid; Biopsy; Brain; Brain Neoplasms; Cell Count; Female; Glioblastoma; Glioma; Human | 2016 |
Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2017 |
Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure.
Topics: Adenocarcinoma; Aged; Aminolevulinic Acid; Biopsy, Needle; Disease-Free Survival; Humans; Immunohist | 2009 |
HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Human | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carbon Radioisotopes; Cystoscopy; Female; Fluorescence; Humans; Male; Neo | 2010 |
[Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients].
Topics: Adrenal Cortex Hormones; Adult; Aminolevulinic Acid; Combined Modality Therapy; Female; Fluorescence | 2010 |
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Contrast Media; Cystoscopy; Disease Progression | 2012 |
Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Female; Follow-Up Studies; Hum | 2011 |
The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurr | 2012 |
Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Dose-Response Relationship, Drug; D | 2013 |
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
Topics: Aged; Aminolevulinic Acid; Canada; Carbon Radioisotopes; Cystoscopy; Diagnosis, Differential; Europe | 2012 |
Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystectomy; Female; Fluorescence; Humans; Light | 2012 |
Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional | 2003 |
[Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2003 |
[The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Female; Fluorescence; Follow-Up Stu | 2004 |
A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional C | 2005 |
Photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Humans; Mitomycin; Neoplasm Rec | 2005 |
5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Disease-Free Survival; Female; | 2005 |
[Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumors].
Topics: Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Female; Fluorescence; Humans; M | 2005 |
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Austria; Carcinoma in Situ; Cystect | 2005 |
Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study.
Topics: Aged; Aminolevulinic Acid; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paget Disease, E | 2006 |
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Fluorescence; Follow-Up Studies; Humans | 2007 |
Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female | 2007 |
Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Bas | 1998 |
Photodynamic cystoscopy for detection of bladder tumors.
Topics: Adenocarcinoma, Papillary; Administration, Intravesical; Aminolevulinic Acid; Biopsy; Cystoscopy; Di | 1999 |
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Follow-Up Studies; Humans; Middle Age | 2000 |
Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female | 2000 |
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 2001 |
Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Endoscopy; Female; Fluorescence; Humans; Male; | 2001 |
Photodynamic therapy for superficial bladder cancer under local anaesthetic.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anesthesia, Local; Anesthetics, Local; Carcinoma, Tran | 2002 |
130 other studies available for aminolevulinic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
The effect of local photodynamic therapy with 5-aminolevulinic acid in the treatment of vaginal intraepithelial lesions with high-risk HPV infection.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Neoplasm Recu | 2022 |
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Photoche | 2022 |
5-aminolevulinic acid and sodium fluorescein in IV ventricle ependymoma surgery: preliminary experience comparing the two techniques.
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Ependymoma; Female; Fluorescein; Humans; Male; Neoplasm | 2022 |
Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ph | 2022 |
The effect of high-risk HPV E6/E7 mRNA on the efficacy of topical photodynamic therapy with 5-aminolevulinic acid for cervical high-grade squamous intraepithelial lesions.
Topics: Aminolevulinic Acid; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Neoplasm Recu | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
Management of patients with positive margin after conization for high-grade cervical intraepithelial lesions.
Topics: Aminolevulinic Acid; Conization; Female; Humans; Margins of Excision; Neoplasm Recurrence, Local; Pa | 2022 |
ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal.
Topics: Acitretin; Aminolevulinic Acid; Anal Canal; Anus Diseases; Condylomata Acuminata; Humans; Neoplasm R | 2022 |
Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervical conization.
Topics: Aminolevulinic Acid; Conization; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; M | 2022 |
Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Glioma; Humans; Mice; Neoplasm Recurrence, Local; Ne | 2023 |
The effect of local photodynamic therapy with 5-aminolevulinic acid in treating different grades of cervical intraepithelial neoplasia.
Topics: Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Papillomavirus Infections; Photoche | 2022 |
Long-term follow up of ALA 10% gel and red-light photodynamic therapy for the treatment of squamous cell carcinoma in situ.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local | 2023 |
Long-term follow up of ALA 10% gel and red-light photodynamic therapy for the treatment of squamous cell carcinoma in situ.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local | 2023 |
Long-term follow up of ALA 10% gel and red-light photodynamic therapy for the treatment of squamous cell carcinoma in situ.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local | 2023 |
Long-term follow up of ALA 10% gel and red-light photodynamic therapy for the treatment of squamous cell carcinoma in situ.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
Topics: Aminolevulinic Acid; Cystectomy; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Musc | 2023 |
5-ALA photodynamic ablation of fibroblastic soft-tissue tumors.
Topics: Aminolevulinic Acid; Fibromatosis, Aggressive; Humans; Neoplasm Recurrence, Local; Photochemotherapy | 2023 |
Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
Topics: Aminolevulinic Acid; Carcinoma; Cystoscopy; Humans; Neoplasm Recurrence, Local; Retrospective Studie | 2023 |
Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Child; Child, Preschool; Female; Humans; Infant | 2019 |
The combination of photodynamic therapy and fractional CO
Topics: Aminolevulinic Acid; Carbon Dioxide; Humans; Laser Therapy; Leukoplakia, Oral; Neoplasm Recurrence, | 2020 |
Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies.
Topics: Aminolevulinic Acid; Animals; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents | 2020 |
Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients.
Topics: Aminolevulinic Acid; China; Humans; Keratosis, Actinic; Neoplasm Recurrence, Local; Photochemotherap | 2020 |
Loop electrosurgical excision procedure followed by 5-aminolevulinic acid photodynamic therapy for cervical intraepithelial neoplasia, a report of six cases.
Topics: Adult; Aminolevulinic Acid; Combined Modality Therapy; Electrosurgery; Female; Humans; Middle Aged; | 2020 |
5-Aminolevulinic acid patch (Alacare) photodynamic therapy for actinic cheilitis: data from a prospective 12-month follow-up study on 21 patients.
Topics: Aminolevulinic Acid; Cheilitis; Follow-Up Studies; Humans; Keratosis, Actinic; Neoplasm Recurrence, | 2020 |
Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Contribution of conventional photodynamic therapy in the treatment of primary cutaneous follicle center lymphoma.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Back; Humans; Lymphoma, Follicular; Male; Middle Age | 2020 |
Advanced application of holmium: YAG laser combined ALA-PDT for the treatment of refractory condylomata acuminata in anal canal.
Topics: Aminolevulinic Acid; Anal Canal; Condylomata Acuminata; Holmium; Humans; Lasers, Solid-State; Neopla | 2020 |
Photodynamic therapy in combination with surgery for the treatment of an extensive squamous cell carcinoma in situ - A case report.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Neopl | 2020 |
Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for the treatment of ulcerative squamous cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy | 2020 |
Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Disease-Free Survival; Female; Fluo | 2020 |
Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases.
Topics: Aminolevulinic Acid; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Papillomavirus Infecti | 2020 |
High Diagnostic Accuracy of Visible 5-ALA Fluorescence in Meningioma Surgery According to Histopathological Analysis of Tumor Bulk and Peritumoral Tissue.
Topics: Aminolevulinic Acid; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrospect | 2021 |
Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Color; Cystoscopy; Disease Progression; Female | 2021 |
High-risk HPV clearance and CIN 3 treated with MAL-PDT: A case report.
Topics: Adult; Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Papillomavirus Infections; P | 2020 |
Photodynamic therapy as an alternative treatment in patients with invasive cutaneous SCC where surgery is not feasible: Single center experience.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy | 2020 |
Self-administered daylight-activated photodynamic therapy for the treatment of hand eczema: A prospective proof-of-concept study.
Topics: Adult; Aminolevulinic Acid; Eczema; Female; Humans; Keratosis, Actinic; Male; Neoplasm Recurrence, L | 2020 |
Clinical efficacy of Mohs surgery combined with topical photodynamic therapy for facial basal cell carcinoma.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Facial Neoplasms | 2020 |
Efficacy of 5-aminolevulinic acid and LED photodynamic therapy in cervical intraepithelial neoplasia: A clinical trial.
Topics: Aminolevulinic Acid; Female; Humans; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing | 2020 |
Isolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glioblastoma; Humans; Neoplasm Recurrence, Local; Photochemot | 2021 |
Photodynamic therapy as a treatment option for multiple pigmented basal cell carcinoma: Long-term follow-up results.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; P | 2021 |
Recurrent high-grade glioma surgery: a multimodal intraoperative protocol to safely increase extent of tumor resection and analysis of its impact on patient outcome.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrenc | 2021 |
Long-term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: A retrospective study.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Neoplasm Recurrence, Local; Photochemotherapy; Phot | 2021 |
Comparative histological and immunohistochemical changes in recurrent nodular basal cell carcinoma after photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy; P | 2021 |
Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
Topics: Aged; Aminolevulinic Acid; Carcinoma; Cystectomy; Cystoscopy; Female; Germany; Health Care Costs; He | 2021 |
In vivo reflectance confocal microscopy for monitoring actinic keratosis treated with 5-aminolevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Microscopy, Confocal; Neoplasm Recurrence, Local; P | 2021 |
Safety and effectiveness of 5-aminolevulinic acid photodynamic therapy combined with fractional micro-plasma radio-frequency treatment for verrucous epidermal nevus: A retrospective study with long-term follow-up.
Topics: Aminolevulinic Acid; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nevus, Sebaceous of Jada | 2021 |
5-Aminolevulinic acid photodynamic therapy for early-stage lip squamous cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; China; Head and Neck Neoplasms; Humans; Lip; Neoplasm | 2021 |
Combination curettage and modified ALA-PDT for multiple basal cell carcinomas of the face and head.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Curettage; Hamartoma Syndrome, Multiple; Humans; Neoplas | 2021 |
[Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)].
Topics: Aged; Aminolevulinic Acid; Cystectomy; Cystoscopy; Humans; Neoplasm Invasiveness; Neoplasm Recurrenc | 2021 |
The application of Wood's lamp combined with 5-aminolevulinic acid for defining tumor margins in patients with extramammary Paget's disease.
Topics: Aminolevulinic Acid; Humans; Margins of Excision; Neoplasm Recurrence, Local; Paget Disease, Extrama | 2021 |
Terapêutica Fotodinâmica com metil-aminolevulinato no tratamento de lesões refractárias de Micose Fungóide: resposta clínica e histológica mantida em dois doentes.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Aged; Aminolevulinic Acid; Humans; Male; Mycosis | 2016 |
Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease Progression; Di | 2017 |
'Real-life experience': recurrence rate at 3 years with Hexvix
Topics: Administration, Intravesical; Aged; Aminolevulinic Acid; Cystectomy; Cystoscopy; Female; Humans; Kap | 2017 |
5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.
Topics: Adult; Aged; Aminolevulinic Acid; ErbB Receptors; Female; Fluorescence; Glioblastoma; Humans; Male; | 2017 |
New combination strategy of photodynamic therapy and surgery in treating recurrent basal cell carcinoma, a case report.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Middle Aged; Mohs Surgery; Neoplasm Recurr | 2018 |
Comparing Topical Treatments for Basal Cell Carcinoma.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Neopla | 2018 |
Efficacy and tolerance of photodynamic therapy for vulvar Paget's disease: a multicentric retrospective study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; Middle Aged; Neopla | 2018 |
Treatment of verrucous carcinoma in penis with topical aminolevulinic acid photodynamic therapy: An effective and safe treatment method.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Verrucous; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 2018 |
Is 5-ALA fluorescence of cerebral metastases a prognostic factor for local recurrence and overall survival?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Foll | 2019 |
High-Definition 3-Dimensional Exoscope for 5-ALA Glioma Surgery: 3-Dimensional Operative Video.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioma; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, | 2020 |
Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Eye; | 2019 |
Combination of electrocoagulation and photodynamic therapy for angiolymphoid hyperplasia with eosinophilia in the external ear.
Topics: Aminolevulinic Acid; Angiolymphoid Hyperplasia with Eosinophilia; Combined Modality Therapy; Ear, Ex | 2019 |
Subependymal spread of recurrent glioblastoma detected with the intraoperative use of 5-aminolevulinic acid: case report.
Topics: Aminolevulinic Acid; Diagnosis, Differential; Glioblastoma; Glioma, Subependymal; Humans; Intraopera | 2013 |
Supraorbital trans-eyebrow craniotomy and fluorescence-guided resection of fronto-basal high grade gliomas.
Topics: Aged; Aminolevulinic Acid; Basal Ganglia; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Craniotomy; | 2013 |
Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Female; Humans; Lasers, Gas; | 2013 |
Diffuse glioma detection.
Topics: Aminolevulinic Acid; Glioblastoma; Glioma, Subependymal; Humans; Male; Neoplasm Recurrence, Local; O | 2013 |
Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cystoscopy; Female; Humans; Male; Mitomycin; Neopl | 2013 |
Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Disease-Free S | 2014 |
Complete remission of two patients with recurrent and wide spread extramammary Paget disease obtained from 5-aminolevulinic acid-based photodynamic therapy and imiquimod combination treatment.
Topics: Aged; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Drug Therapy, Combination; Genita | 2014 |
No 5-ALA fluorescence seen in a recurrent papillary tumour of the pineal region (PTPR).
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Humans; Neoplasm Recurrence, Loca | 2015 |
5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Disease Progression; Female; Fluorescence; Glioblastoma; | 2015 |
Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Case-Control Studies; Feasibility Studies; Female | 2015 |
Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Topics: Aminolevulinic Acid; Budgets; Costs and Cost Analysis; Cystoscopy; Disease Progression; Humans; Neop | 2016 |
Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cohort Studies; Confiden | 2016 |
Laser biospectroscopy and 5-ALA fluorescence navigation as a helpful tool in the meningioma resection.
Topics: Adult; Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Meningeal Neoplasms; Meningiom | 2016 |
Blue Light Cystoscopy Should be Used Routinely for Bladder Cancer Detection: Pro.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Fluorescence; Humans; Neoplasm Recurrence, Local; Urina | 2016 |
Long-term follow-up of patients with basal cell carcinoma after successful treatment with intralesional photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Inject | 2016 |
Treatment of Sweat gland carcinoma with Topical Aminolevulinic Acid Photodynamic therapy: An effective treatment method to improve surgical outcomes.
Topics: Aminolevulinic Acid; Foot; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Photochemotherapy; | 2017 |
Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squ | 2009 |
Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Cystoscopy; Humans; Mic | 2009 |
Blue-sky thinking about blue-light cystoscopy.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Photo | 2009 |
Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Cohort Studies; Combined Modality Thera | 2009 |
Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; F | 2009 |
Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; B | 2010 |
Editorial comment.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; Humans; Neoplasm Recurrence, Loca | 2009 |
[Clinical experience with transurethral resection of bladder tumor (TUR-Bt) guided by photodynamic diagnosis (PDD)].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Disease-Free Survival; F | 2009 |
New bladder cancer removal technique reduces recurrence.
Topics: Aminolevulinic Acid; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2010 |
Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas.
Topics: Adult; Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Meningeal Neoplasms; Meningiom | 2010 |
Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate.
Topics: Aged; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Follow-Up Studies; Humans; Kaplan- | 2010 |
Confocal microscopy for the histological fluorescence pattern of a recurrent atypical meningioma: case report.
Topics: Aminolevulinic Acid; Diagnostic Imaging; Female; Fluorescent Antibody Technique; Humans; Meningeal N | 2011 |
Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Chi-Square Distribution; China; Facial Neoplasms | 2011 |
Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Hum | 2012 |
High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2012 |
Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
Topics: Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cel | 2012 |
Editorial comment.
Topics: Aminolevulinic Acid; Cystoscopy; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; | 2012 |
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Carcinoma, Papillary; Cost-Benefit Analysis; Cystoscopy; | 2012 |
Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
Topics: Adult; Aminolevulinic Acid; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; | 2012 |
Editorial comment.
Topics: Aminolevulinic Acid; Cystectomy; Female; Humans; Light; Male; Neoplasm Recurrence, Local; Radionucli | 2012 |
Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dermoscopy; Female; Foll | 2013 |
Daylight-mediated photodynamic therapy of basal cell carcinomas - an explorative study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Back; Carcinoma, Basal Cell; Facial Neoplasms; | 2014 |
Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma in Situ; Fluorescence; Humans | 2002 |
Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; False Positi | 2002 |
Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; I | 2003 |
Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.
Topics: Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Microscopy, F | 2003 |
Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; England | 2003 |
Recurrence rate of basal cell carcinoma after topical aminolevulinic acid-based photodynamic therapy.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Neo | 2004 |
5-Aminolevulinic acid-based photodynamic therapy for the treatment of two patients with extramammary Paget's disease.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Genital Neoplasms, Female; Genital Neoplasms, | 2005 |
Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy.
Topics: Adult; Aminolevulinic Acid; Carcinoma in Situ; Female; Gynecologic Surgical Procedures; Humans; Lase | 2006 |
Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Neoplasm Recurrence, | 2006 |
Aminolevulinic acid 585 nm pulsed dye laser photodynamic treatment of laryngeal keratosis with atypia.
Topics: Administration, Topical; Aged; Ambulatory Care; Aminolevulinic Acid; Biopsy; Cell Transformation, Ne | 2007 |
Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report.
Topics: Aged; Aminolevulinic Acid; Craniotomy; Female; Fluorescence; Humans; Magnetic Resonance Imaging; Men | 2007 |
Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Feasibility Studies; Glioma; Humans; Magnetic Res | 2007 |
Preliminary results of intraoperative photodynamic therapy with 5-aminolevulinic acid in dogs with prostate carcinoma.
Topics: Aminolevulinic Acid; Animals; Combined Modality Therapy; Dog Diseases; Dogs; Intraoperative Care; Ma | 2008 |
Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans | 2008 |
Thioredoxin upregulation by 5-aminolaevulinic acid-based photodynamic therapy in human skin squamous cell carcinoma cell line.
Topics: Aminolevulinic Acid; Analysis of Variance; Blotting, Western; Carcinoma, Squamous Cell; Caspase 3; C | 2008 |
Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Ce | 1995 |
[Use of photodynamic laser therapy in gynecology].
Topics: Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Genital Neoplasms, Female; Genitalia, F | 1995 |
Adjuvant intraoperative photodynamic therapy diminishes the rate of local recurrence in a rat mammary tumour model.
Topics: Adenocarcinoma; Aminolevulinic Acid; Analysis of Variance; Animals; Chemotherapy, Adjuvant; Female; | 1995 |
[Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1994 |
Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Follow-Up Studies; Humans; M | 1996 |
[The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carci | 1997 |
[Fluorescence--endoscopy in carcinoma of the urinary bladder].
Topics: Aminolevulinic Acid; Cystoscopes; Humans; Neoplasm Recurrence, Local; Precancerous Conditions; Urina | 1998 |
Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1999 |
Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Cat Diseases; Cats; | 2001 |
Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; N | 2001 |
A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Esth | 2001 |
Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Femal | 2001 |
Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Female; Humans; Hypopharyngeal Neoplasms; Laryngeal N | 2001 |
Comparison of the bladder tumour antigen test with photodynamic diagnosis in patients with pathologically confirmed recurrent superficial urinary bladder tumours.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antigens, Neoplasm; Biomarkers, Tumor; Cystosco | 2002 |
[Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Huma | 2002 |
Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment.
Topics: Administration, Cutaneous; Adult; Aged; Aminolevulinic Acid; Clinical Trials, Phase II as Topic; Fac | 2002 |
5-Aminolevulinic Acid-Guided Surgery for Recurrent Supratentorial Pediatric Neoplasms.
Topics: Aminolevulinic Acid; Brain Neoplasms; Child; Child, Preschool; Female; Fluorescent Dyes; Humans; Lev | 2020 |